Lung Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG031 MIFTS: 51	Lung Benign Neoplasm Categories: Cancer diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm ¹¹ ¹⁴

Lung Neoplasms ⁴³ ⁷¹

Tumor of the Lung ¹¹

Lung Tumor ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3683

MeSH ⁴³ D008175

NCIt ⁴⁹ C3200

SNOMED-CT ⁶⁸ 126713003

UMLS ⁷¹ C0024121

Sources

Summaries for Lung Benign Neoplasm

MalaCards based summary: Lung Benign Neoplasm, also known as lung neoplasms, is related to lung adenoma and carcinoid syndrome, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Overview of interferons-mediated signaling pathway and Malignant pleural mesothelioma. The drugs Midazolam and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are Decreased viability and Reduced mammosphere formation

Sources

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 950)

#	Related Disease	Score	Top Affiliating Genes
1	lung adenoma	31.7	TP53 SFTPC SCGB1A1 NKX2-1 KRAS HRAS
2	carcinoid syndrome	31.5	SYP ENO2 CHGA
3	carcinoid tumors, intestinal	31.5	SYP NKX2-1 ENO2 CHGA
4	inflammatory myofibroblastic tumor	31.4	TP53 MET EGFR
5	granular cell tumor	31.1	SYP NKX2-1 ENO2
6	pulmonary sclerosing hemangioma	30.8	TP53 SYP NKX2-1 CHGA
7	sclerosing hemangioma	30.7	TP53 SYP NKX2-1 CHGA
8	acinar cell carcinoma	30.6	SYP KRT7 CHGA
9	hemangioblastoma	30.5	SYP ENO2 EGFR
10	malignant peripheral nerve sheath tumor	30.5	TP53 MET KRT7 EGFR CDKN2A
11	benign mesothelioma	30.4	NKX2-1 KRT7 KRT20 CDKN2A
12	neuroendocrine tumor	30.4	SYP NKX2-1 NCAM1 KRT20 GRP ENO2
13	adenofibroma	30.4	TP53 KRT7 KRAS
14	sarcoma	30.4	TP53 MET KRAS HRAS ENO2
15	myoblastoma	30.4	SYP ENO2
16	oncocytoma	30.3	SYP KRT7 KRT20
17	tuberous sclerosis	30.3	TP53 SYP ENO2 CHGA
18	breast fibroadenoma	30.3	TP53 RASSF1 EGFR
19	bronchus cancer	30.3	KRT7 GRP FHIT ENO2 EGFR
20	islet cell tumor	30.2	SYP NCAM1 ENO2 CHGA
21	thymic carcinoma	30.2	SYP NKX2-1 KRT7 EGFR
22	myoma	30.2	TP53 KRAS ENO2 EGFR
23	laryngeal benign neoplasm	30.2	TP53 EGFR CDKN2A
24	squamous cell carcinoma	30.2	TP53 NKX2-1 KRT7 KRAS HRAS FHIT
25	pleomorphic adenoma	30.2	TP53 FHIT ENO2
26	rectum cancer	30.2	TP53 KRT20 KRAS HRAS EGFR
27	ewing sarcoma	30.2	TP53 SYP RASSF1 NCAM1 GRP ENO2
28	lung disease	30.2	SFTPC SCGB1A1 NKX2-1 GRP ENO2 CHGA
29	neurofibromatosis	30.1	TP53 KRAS HRAS EGFR CDKN2A
30	lung giant cell carcinoma	30.1	NKX2-1 KRT7 KRAS EGFR
31	alveoli adenoma	30.1	SFTPC SCGB1A1 NKX2-1
32	cystadenoma	30.1	SYP KRT7 KRT20 CHGA
33	mixed cell type cancer	30.1	TP53 SYP KRT7 KRAS HRAS ENO2
34	pleural disease	30.1	TP53 EGFR CDKN2A
35	ascending colon cancer	30.1	KRT7 KRAS HRAS
36	rectal benign neoplasm	30.1	TP53 KRT7 KRT20 KRAS HRAS EGFR
37	hemangioma	30.1	TP53 SYP NKX2-1 KRT7 KRAS ENO2
38	lung squamous cell carcinoma	30.0	TP53 RARB KRAS HRAS EGFR CDKN2A
39	exanthem	30.0	KRAS HRAS EGFR
40	transverse colon cancer	30.0	KRT20 KRAS HRAS
41	appendix adenocarcinoma	30.0	TP53 SYP KRT7 KRT20 KRAS HRAS
42	pleural cancer	30.0	TP53 EGFR CDKN2A
43	skin benign neoplasm	30.0	TP53 KRT7 KRT20 HRAS ENO2
44	adenocarcinoma in situ	30.0	TP53 NKX2-1 KRT7 KRAS HRAS EGFR
45	papillary adenocarcinoma	30.0	TP53 NKX2-1 KRT7 KRAS HRAS
46	sweat gland cancer	30.0	TP53 SYP KRT7 KRT20
47	lung oat cell carcinoma	30.0	TP53 SYP ENO2 CHGA
48	breast adenocarcinoma	30.0	TP53 KRT7 KRAS HRAS EGFR CDKN2A
49	pulmonary blastoma	30.0	TP53 SYP NKX2-1 KRAS EGFR CHGA
50	mucinous adenocarcinoma	30.0	TP53 NKX2-1 KRT7 KRT20 KRAS HRAS

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:

Sources

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:

hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

²⁵ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	CDKN2A CHGA EGFR ENO2 FHIT GRP
2	no effect	GR00402-S-2	10.18	CDKN2A CHGA EGFR FHIT HRAS KRAS
3	Decreased viability	GR00055-A-1	10.11	EGFR HRAS KRAS NCAM1
4	Decreased viability	GR00055-A-2	10.11	EGFR HRAS KRAS
5	Decreased viability	GR00055-A-3	10.11	KRAS
6	Decreased viability	GR00106-A-0	10.11	KRAS
7	Decreased viability	GR00221-A-1	10.11	EGFR HRAS KRAS
8	Decreased viability	GR00221-A-2	10.11	HRAS KRAS
9	Decreased viability	GR00221-A-3	10.11	HRAS
10	Decreased viability	GR00221-A-4	10.11	EGFR
11	Decreased viability	GR00301-A	10.11	KRAS
12	Decreased viability	GR00381-A-1	10.11	KRAS
13	Reduced mammosphere formation	GR00396-S	9.5	CHGA EGFR HRAS KRAS KRT7 NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

⁴⁵ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.32	CDKN2A CHGA EGFR ENO2 GRP HRAS
2	neoplasm	MP:0002006	10.3	CDKN2A EGFR FHIT HRAS KRAS MET
3	homeostasis/metabolism	MP:0005376	10.25	CDKN2A CHGA EGFR FHIT HRAS KRAS
4	normal	MP:0002873	10.21	EGFR HRAS KRAS MET NKX2-1 RARB
5	no phenotypic analysis	MP:0003012	10.19	CDKN2A CHGA EGFR HRAS KRAS MET
6	endocrine/exocrine gland	MP:0005379	10.15	CDKN2A CHGA EGFR HRAS KRAS MET
7	renal/urinary system	MP:0005367	10.11	CHGA EGFR HRAS KRAS KRT7 MET
8	muscle	MP:0005369	10.03	CDKN2A CHGA EGFR HRAS KRAS MET
9	cellular	MP:0005384	10.03	CDKN2A EGFR ENO2 KRAS KRT7 MET
10	digestive/alimentary	MP:0005381	10.02	CDKN2A EGFR FHIT HRAS KRAS MET
11	cardiovascular system	MP:0005385	9.93	CDKN2A CHGA EGFR GRP HRAS KRAS
12	respiratory system	MP:0005388	9.77	CDKN2A EGFR ENO2 GRP HRAS KRAS
13	mortality/aging	MP:0010768	9.5	CDKN2A CHGA EGFR FHIT HRAS KRAS

Sources

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 786)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Ipratropium

Approved, Experimental

Phase 4

22254-24-6, 60205-81-4

657309 3746

Terbutaline

Approved

Phase 4

23031-25-6

5403

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Remifentanil

Approved

Phase 4

132875-61-7

60815

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Alfentanil

Approved, Illicit

Phase 4

71195-58-9

51263

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

581 12035

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Tropisetron

Approved, Investigational

Phase 4

105826-92-4, 89565-68-4

656665

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Desflurane

Approved

Phase 4

57041-67-5

42113

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Cisatracurium

Approved, Investigational

Phase 4

96946-41-7

62887

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Clonidine

Approved

Phase 4

4205-91-8, 4205-90-7

2803 20179

Droperidol

Approved, Vet_approved

Phase 4

548-73-2

3168

Scopolamine

Approved, Investigational

Phase 4

51-34-3

153311 3000322

Olanzapine

Approved, Investigational

Phase 4

132539-06-1

135398745 4585

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Acetaminophen

Approved

Phase 4

103-90-2

1983

Topotecan

Approved, Investigational

Phase 4

123948-87-8, 119413-54-6

60699 60700

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5, 15307-79-6

3033

Vemurafenib

Approved

Phase 4

918504-65-1

42611257

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Ibandronate

Approved, Investigational

Phase 4

114084-78-5

60852

Aspartic acid

Approved, Nutraceutical

Phase 4

56-84-8

5960

Imidacloprid

Vet_approved

Phase 4

105827-78-9

86418

Epinephryl borate

Phase 4

Pharmaceutical Solutions

Phase 4

Endostar protein

Phase 4

Calcium heparin

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

Analgesics, Non-Narcotic

Phase 4

Anti-Anxiety Agents

Phase 4

GABA Modulators

Phase 4

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Sodium Channel Blockers

Phase 4

Diuretics, Potassium Sparing

Phase 4

Interventional clinical trials:

(show top 50) (show all 6131)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer	Unknown status	NCT02031601	Phase 4	Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin)
2	A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer	Unknown status	NCT02996214	Phase 4	Paclitaxel Liposome;Gemcitabine;Cisplatin
3	PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice	Unknown status	NCT00675168	Phase 4
4	Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP	Unknown status	NCT03890055	Phase 4	Anlotinib Hydrochloride
5	Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study	Unknown status	NCT03792503	Phase 4	Apatinib;Pemetrexed
6	Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study	Unknown status	NCT02348450	Phase 4	Irinotecan;Etoposide;Cisplatin
7	Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD	Unknown status	NCT02504801	Phase 4	Budesonide
8	Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study	Unknown status	NCT02480634	Phase 4	Zoledronic acid
9	Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies	Unknown status	NCT04036721	Phase 4	Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
10	Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics	Unknown status	NCT03264794	Phase 4	Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial;Gefitinib tablets (Yi Ruisha），First medication;Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
11	Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research	Unknown status	NCT02513355	Phase 4	Changchun marina;cisplatin;Taxol;parapl
12	A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)	Unknown status	NCT01028729	Phase 4	Endostar;Gemcitabine-Cisplatin chemotherapy
13	The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer	Unknown status	NCT02346318	Phase 4	Compound Kushen Injection
14	Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration	Unknown status	NCT01381627	Phase 4	Remifentanil;Dexmedetomidine
15	The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )	Unknown status	NCT01211002	Phase 4	radiotherapy / EP combined with recombinant human endostatin
16	A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer	Unknown status	NCT02195453	Phase 4	Yangzhengxiaoji Capsule;Placebo Capsule
17	Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study	Unknown status	NCT02194556	Phase 4	Sequential and maintenance icotinib;Maintenance icotinib
18	Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin	Unknown status	NCT01336192	Phase 4	Gemcitabine;Best supportive care
19	A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients	Completed	NCT02744664	Phase 4	Icotinib
20	Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer.	Completed	NCT00925444	Phase 4
21	Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial.	Completed	NCT01658280	Phase 4
22	"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study	Completed	NCT00338481	Phase 4	Morphine p.o.;Morphine s.c.
23	Enhancing Tobacco Use Treatment for African American Light Smokers	Completed	NCT00666978	Phase 4	bupropion hydrochloride
24	Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer	Completed	NCT00451906	Phase 4	Platinum-based chemotherapy;Bevacizumab [Avastin]
25	A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy	Completed	NCT00770588	Phase 4	Gefitinib;Placebo
26	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Completed	NCT00762346	Phase 4	zometa
27	A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC).	Completed	NCT03853551	Phase 4	Osimertinib
28	Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C): A Feasibility Study	Completed	NCT04074460	Phase 4	Propofol;isoflurane, sevoflurane or desflurane
29	A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates	Completed	NCT00765687	Phase 4	bisphosphates
30	A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung	Completed	NCT00747773	Phase 4
31	Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation	Completed	NCT02962999	Phase 4	Ketamine;Saline
32	Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic	Completed	NCT00440960	Phase 4	propofol;midazolam;alfentanil;lidocaine
33	Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer	Completed	NCT00686322	Phase 4	Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
34	Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients	Completed	NCT02275702	Phase 4	Dexamethasone IV;Saline solution
35	Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy	Completed	NCT00380718	Phase 4	pemetrexed
36	A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis	Completed	NCT00099541	Phase 4	zoledronic acid
37	An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	Completed	NCT01000740	Phase 4
38	Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.	Completed	NCT02316327	Phase 4	gemcitabine, cisplatin and bevacizumab
39	ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study	Completed	NCT03550482	Phase 4
40	A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer	Completed	NCT01066884	Phase 4	erlotinib [Tarceva]
41	A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC	Completed	NCT00115206	Phase 4	Neulasta® (pegfilgrastim)
42	Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response	Completed	NCT03655834	Phase 4	Pemetrexed
43	An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer	Completed	NCT00949910	Phase 4	Erlotinib
44	Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer	Completed	NCT00883675	Phase 4	Docetaxel-Carboplatin
45	Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer	Completed	NCT02497118	Phase 4	Endostatin;Vinorelbine;Cisplatin
46	Comparing the Lozenge to the Patch for Smoking Cessation	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
47	Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease	Completed	NCT02476526	Phase 4	Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
48	Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients	Completed	NCT01060137	Phase 4	fentanyl matrix
49	Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer	Completed	NCT01020786	Phase 4	Pemetrexed;Carboplatin
50	A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy	Completed	NCT01230710	Phase 4	Erlotinib

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carboplatin

Carmustine

Cholecalciferol

Cisplatin

CISPLATIN PWDR

Cyclophosphamide

Etoposide

etoposide phosphate

Ifosfamide

Lomustine

Methotrexate

Methotrexate Sodium

Paclitaxel

Procarbazine

Procarbazine Hydrochloride

Teniposide

Vinblastine

Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Sources

Genetic Tests for Lung Benign Neoplasm

Sources

Anatomical Context for Lung Benign Neoplasm

Organs/tissues related to Lung Benign Neoplasm:

MalaCards : Lung, Lymph Node, Brain, T Cells, Breast, Liver, Prostate

Sources

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 7767)

#	Title	Authors	PMID	Year
1	Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. ⁵³ ⁶²	Wright ME...Albanes D	20484175	2010
2	Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. ⁵³ ⁶²	Wang J...Ma PC	20207772	2010
3	The neural cell adhesion molecule is involved in the metastatic capacity in a murine model of lung cancer. ⁵³ ⁶²	Campodonico PB...Todaro LB	20191608	2010
4	[A case of metastatic lung tumor with multiple ground glass opacities on chest CT]. ⁵³ ⁶²	Kunikata S...Chida K	20432971	2010
5	Fhit regulates invasion of lung tumor cells. ⁵³ ⁶²	Joannes A...Nawrocki-Raby B	19935706	2010
6	The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. ⁵³ ⁶²	Chenau J...Seve M	19639960	2009
7	Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients. ⁵³ ⁶²	Gao W...Keohavong P	19072763	2009
8	Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer. ⁵³ ⁶²	Chien WP...Lee H	19434453	2009
9	Arsenic activates EGFR pathway signaling in the lung. ⁵³ ⁶²	Andrew AS...Duell EJ	19168569	2009
10	EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. ⁵³ ⁶²	Sartori G...Rossi G	19289583	2009
11	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. ⁵³ ⁶²	Gow CH...Shih JY	19088172	2009
12	Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. ⁵³ ⁶²	Zhang G...Srinivas H	19106194	2009
13	Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. ⁵³ ⁶²	Memon AA...Nexo E	19155297	2009
14	Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. ⁵³ ⁶²	Geurts TW...Brakenhoff RH	19188169	2009
15	Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. ⁵³ ⁶²	Duan W...Villalona-Calero MA	19440353	2009
16	Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. ⁵³ ⁶²	Cheng YW...Lee H	19010833	2008
17	Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer. ⁵³ ⁶²	Chen CM...Huang SF	18651255	2008
18	Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. ⁵³ ⁶²	Nemenoff R...Keith RL	19138979	2008
19	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. ⁵³ ⁶²	Zerbe LK...Malkinson AM	18030469	2008
20	A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. ⁵³ ⁶²	Adiseshaiah P...Reddy SP	18288638	2008
21	Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. ⁵³ ⁶²	Stabile LP...Siegfried JM	18645002	2008
22	Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549. ⁵³ ⁶²	Liu G...Fu S	18343694	2008
23	Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice. ⁵³ ⁶²	Jin H...Cho MH	18292798	2008
24	Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. ⁵³ ⁶²	Kitahashi T...Wakabayashi K	18271921	2008
25	Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel. ⁵³ ⁶²	Odonkor CA...Achilefu S	19238186	2008
26	Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. ⁵³ ⁶²	Shibuya K...O'Reilly MS	17889445	2007
27	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. ⁵³ ⁶²	Gong Y...Pao W	17927446	2007
28	p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. ⁵³ ⁶²	Pei XH...Xiong Y	17409423	2007
29	Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. ⁵³ ⁶²	Huang WC...Chen CC	17434128	2007
30	mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. ⁵³ ⁶²	Inoue S...Ramesh R	17235306	2007
31	Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells. ⁵³ ⁶²	Ghosh AK...Ray RB	17178888	2006
32	Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. ⁵³ ⁶²	Tang W...Zhong JJ	17007887	2006
33	Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. ⁵³ ⁶²	Miura N...Shiota G	17052260	2006
34	CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. ⁵³ ⁶²	Parise RA...Hershberger PA	16708384	2006
35	Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. ⁵³ ⁶²	Huang LJ...Yi H	16876904	2006
36	Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. ⁵³ ⁶²	Duan W...Villalona-Calero MA	16934800	2006
37	Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. ⁵³ ⁶²	Zhang W...Siegfried JM	17409930	2006
38	Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. ⁵³ ⁶²	Fulzele SV...Singh M	16902813	2006
39	Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. ⁵³ ⁶²	Muruganandham M...Koutcher JA	16928815	2006
40	Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. ⁵³ ⁶²	Floyd HS...Miller MS	16482519	2006
41	Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. ⁵³ ⁶²	Cui X...Hirano S	16543296	2006
42	Non-destructive micromethod for MRP1 functional assay in human lung tumor cells. ⁵³ ⁶²	Stehfest E...Foth H	16374597	2006
43	Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. ⁵³ ⁶²	Yoo J...Im DS	16144019	2006
44	A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. ⁵³ ⁶²	Wang Y...You M	16247444	2006
45	Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. ⁵³ ⁶²	Kiewlich D...Zajchowski DA	16533422	2006
46	Advances in noninvasive pulmonary gene therapy. ⁵³ ⁶²	Densmore CL	16472094	2006
47	The differential effects of mutant p53 alleles on advanced murine lung cancer. ⁵³ ⁶²	Jackson EL...Jacks T	16288016	2005
48	Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood. ⁵³ ⁶²	Yamamoto O...Abe S	16085219	2005
49	Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. ⁵³ ⁶²	Takechi T...Fukushima M	15944764	2005
50	Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblast. ⁵³ ⁶²	Mukhopadhyay NK...Jaklitsch MT	16202213	2005

Sources

Genes for Lung Benign Neoplasm

Genes related to Lung Benign Neoplasm (0 elite genes):

(show all 30)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NKX2-1	NK2 Homeobox 1	Protein Coding	16.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11668468 15098255 12930693 (more) 19620839 11957142 15257545 16540736 10721419 15084379 12011259 19740516 12407752 10895813 14745718 17425388 18801593 11679943 16570563 19747750
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	15.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11528387 16410370 12650907 (more) 17510423 11559534 15753357 20101149 19887599 17693665 11016621 15572290 15026325 15021904
3	TP53	Tumor Protein P53	Protein Coding	14.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12907609 10446974 15805253 (more) 9255578 8142008 17477876 8600505 10706103 19072763 18712569 8614143 12591728 1543544 11559534 12650907 15902970 1656762 16865671 12552590 8623922 16288016 8137262 15564288 10861503 7586163 8504472 2223098 18006810 19941079 10207632 12711114 10350439 16410370 1620551 8353844 8170984 8014012 7969181 16934800 10953344 10353731 9230291 9052408 9052381 20514470 18555750 17530187 17007887 9289861 8959323 8389245 1444195 1312896 17409930 17380445 16247444 15564291 19995647 17693665 16482519 11726024 11414196 11107065 7923210 1331352 19639960 16472094 15547185 10475393 10223567 10091733 9784987 9675232 16458448 15072824 12844488 11815976 11474498 11195464 10368638 15572290 9637795 8843680 7545909 8317547 1486840 18292798 14617796 13679864 10937049 10100998 9307295 19434453 19188169 16395694 11035769 16675590 7855100 7677185
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	13.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1313613 17477876 19088172 (more) 18271921 17927446 20207772 7855100 12631609 12652739 15032719 15753357 16467080 18030469 15489898 15476598 11879619 19723643 19155297 18651255 16642476 17889445 19328671 20007486 19168569 19289583 18992960 12711118 8297109 19887599 19995647 17913856 17052260 16540667 16730237 9703905 17256054 16198442 18721806 17369752 18093943 19096299 1356016 14757534 16230409
5	SCGB1A1	Secretoglobin Family 1A Member 1	Protein Coding	13.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12826312 1394139 9191473
6	KRT7	Keratin 7	Protein Coding	12.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11668468 16570563 11745209 (more) 11679943 10987260 12930693 20432971
7	SFTPC	Surfactant Protein C	Protein Coding	12.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1394139 7524342 16085219 (more) 8248207
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	11.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9054597 9659580 15455389 (more) 11872642 16533425 9589349 9032263 9659578 16482519 9816033 16543296 19440353 10649246 8758904 9731504 16705183 12185599 9659583 11414196 11920642 17140695 15073103
9	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	11.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8620533 9393735 19935706 (more) 8653678 9740075 12007194 19418484 14731325 17693665 19096006 17140695 17255269 9850082 19267103
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	11.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16410370 19440353 18758463
11	SYP	Synaptophysin	Protein Coding	11.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10987260 11417996 2170973
12	RASSF1	Ras Association Domain Family Member 1	Protein Coding	10.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17477876 11306494 15711568 (more) 11668500 15073103 16543296
13	RARB	Retinoic Acid Receptor Beta	Protein Coding	10.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10834944 17140695 14656941 (more) 10944551 20484175 1717924
14	CHGA	Chromogranin A	Protein Coding	10.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1668786 8427030 11417996 (more) 2170973
15	ENO2	Enolase 2	Protein Coding	10.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7564279 8616474 18998332 (more) 9329552
16	GRP	Gastrin Releasing Peptide	Protein Coding	9.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1698239 1668786 8718793 (more) 8132585 1752059 15750618
17	KRT20	Keratin 20	Protein Coding	9.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11668468 18626520 16570563 (more) 20432971 12011259 11679943 11745209
18	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	9.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10069465 18712569 16533425 (more) 9714064 18555750 15073103 12185595
19	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	9.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14737093 19723643
20	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	9.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9777989 20191608 8194895 (more) 1314782 2153450
21	TERT	Telomerase Reverse Transcriptase	Protein Coding	9.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15837730 16202213 19010833
22	NQO1	NAD(P)H Quinone Dehydrogenase 1	Protein Coding	9.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12370763 9748120 1324793 (more) 8195022 8205540 1908440 8221686
23	STK11	Serine/Threonine Kinase 11	Protein Coding	9.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19176640 17521700 19229701 (more) 15077168 15021901
24	RB1	RB Transcriptional Corepressor 1	Protein Coding	9.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9659580 12612881 7855100 (more) 11030152 16613540 10649246 9659583 8758904 7923210 10475393 9589349 9476905
25	CASP3	Caspase 3	Protein Coding	9.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19238186 16144019 16902813
26	CTSB	Cathepsin B	Protein Coding	8.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11147599 2320181 8074490 (more) 7612192 1674512 8074469 16380983 9402478 8402725 15878337 8014475
27	NUDT1	Nudix Hydrolase 1	Protein Coding	8.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15126288
28	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	8.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17909032 1353700 15073103
29	PTGIS	Prostaglandin I2 Synthase	Protein Coding	8.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19138979 15313935
30	AKR1C1	Aldo-Keto Reductase Family 1 Member C1	Protein Coding	8.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17163506 16876904

Sources

Variations for Lung Benign Neoplasm

Sources

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Sources

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.52	TP53 RARB MET KRAS HRAS EGFR
2	Malignant pleural mesothelioma ⁷⁴	12.49	TP53 RASSF1 MET HRAS EGFR CDKN2A
3	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.39	TP53 KRAS HRAS EGFR
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.36	TP53 KRAS HRAS EGFR
5	MAPK signaling pathway ⁷⁴	12.3	TP53 KRAS HRAS EGFR
6	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.27	TP53 MET KRAS HRAS EGFR
7	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.18	TP53 RASSF1 RARB KRAS HRAS FHIT
8	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.09	TP53 MET KRAS HRAS EGFR
9	Ras signaling ⁷⁴	12.03	RASSF1 MET KRAS HRAS EGFR
10	mTOR Signaling ⁶⁵	12	TP53 MET KRAS EGFR
11	Gastrin signaling pathway ⁷⁴	11.77	CDKN2A CHGA EGFR HRAS KRAS
12	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.69	TP53 KRAS HRAS
13	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.53	KRAS HRAS EGFR
14	p53 pathway ⁶¹	11.47	TP53 RASSF1 CDKN2A
15	Posttranslational regulation of adherens junction stability and dissassembly ⁶¹	11.44	MET HRAS EGFR
16	Head and neck squamous cell carcinoma ⁷⁴	11.42	TP53 KRAS HRAS EGFR CDKN2A
17	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.39	EGFR HRAS KRAS
18	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.32	MET KRAS HRAS
19	a6b1 and a6b4 Integrin signaling ⁶¹	11.29	MET HRAS EGFR
20	Aryl hydrocarbon receptor pathway ⁷⁴	11.18	KRAS HRAS EGFR
21	Transcription_Transcription factor Tubby signaling pathways ²²	11.15	TP53 KRAS HRAS EGFR
22	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.1	EGFR HRAS KRAS
23	G-protein signaling_K-RAS regulation pathway ²²	11.08	EGFR KRAS RASSF1
24	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11	MET KRAS HRAS EGFR
25	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.71	KRAS HRAS
26	Bladder cancer ⁷⁴	10.7	TP53 RASSF1 KRAS HRAS EGFR CDKN2A

Sources

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	GO:1900738	9.46	GRP CHGA
2	regulation of long-term neuronal synaptic plasticity	GO:0048169	9.43	SYP KRAS HRAS
3	Ras protein signal transduction	GO:0007265	9.32	TP53 RASSF1 KRAS HRAS CDKN2A
4	positive regulation of miRNA maturation	GO:1903800	9.26	TP53 EGFR